COBRE Center for Antimicrobial Resistance and Therapeutic Discovery - Administrative Core

COBRE 抗菌素耐药性和治疗发现中心 - 行政核心

• 批准号: 10488622
• 负责人: ERIKA M D'AGATA
• 金额: $ 45.71万
• 依托单位: MIRIAM HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-18 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10488622
• 关键词: Advisory Committees; Antimicrobial Resistance; Award; Biological Sciences; Centers of Research Excellence; Communication; Conflict (Psychology); Core Facility; Ensure; Environment; Faculty; Fostering; Funding; Goals; Grant; Hospitals; Individual; Infrastructure; Institution; Laboratories; Mentors; Mission; Monitor; National Institute of General Medical Sciences; Outcome; Peer Review; Performance; Phase; Philosophy; Process; Publications; Research; Research Personnel; Resistance development; Rhode Island; Science; Services; Therapeutic; United States National Institutes of Health; Universities; Work; base; design; drug development; faculty mentor; organizational structure; outreach; professor; programs; senior faculty

The Miriam Hospital enthusiastically recommends Erika D’Agata, MD, MPH of to be appointed as The Center for Antimicrobial Resistance and Therapeutic Discover (CARTD) Program Director/Principal Investigator (PD/PI) effective March 1, 2023. Administrative Core Summary/Abstract The Administrative Core will provide financial, scientific and technologic stewardship of the COBRE Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital. Core Director Mylonakis, with the assistance of Deputy Director Nau, will establish overall programmatic goals. These goals and progress toward accomplishing them will be monitored by the Steering Committee, External Advisory Committee, Senior Faculty Mentoring and Advisory Committee (SFMAC) and Program Staff at NIGMS. Our Center’s overall mission is to foster an environment that inspires individuals to pursue rigorous laboratory science by providing technical and mentoring support through our core facilities. We will pursue the following specific aims: (1): The Core will maintain an organizational structure that ensures effective communication between the supervisory, scientific, administrative and service oriented components of the COBRE. (2): The Core will devise strategies to increase the use of CARDT Cores to allow self-sustainability by the end of Phase III. (3): The Core will provide a rigorous mentoring infrastructure to all CARDT principal/pilot investigators. (4): The Core will manage a Pilot Grants Program designed to support the most meritorious research on antimicrobial resistance and drug development.

Miriam医院热情推荐Erika D 'Agata，MD，MPH被任命为抗菌素耐药性和治疗发现中心（CARTD）项目主任/主要研究者（PD/PI），2023年3月1日生效。 行政核心 总结/摘要 行政核心将提供财政、科学和技术管理， COBRE抗菌药物耐药性和治疗发现中心（CARTD） 医院核心主任Mylonakis将在副主任Nau的协助下， 总体方案目标。这些目标和实现这些目标的进展将是 由指导委员会，外部咨询委员会，高级教师指导监督 和咨询委员会（SFMAC）和项目工作人员在NIGMS。我们中心的总体使命是 培养一个激励个人追求严格的实验室科学的环境， 通过我们的核心设施提供技术和指导支持。我们将继续 以下具体目标：（1）：核心将维持一个组织结构，以确保 监督、科学、行政和服务导向之间的有效沟通 COBRE的组成部分。(2)：核心小组将制定战略，增加CARDT的使用 在第三阶段结束时实现自我维持的核心。(3)：核心将提供严格的 为所有CARDT主要/试点调查员提供基础设施指导。(4)：核心将管理一个 试点赠款计划，旨在支持最有价值的抗菌研究 耐药性和药物开发。